Objective：To observe the efficacy of entecavir combined with matrine in the treatment of HBeAg-positive related chronic hepatitis B. Methods：Totally 109 patients with HBeAg-positive related chronic hepatitis B were randomly divided into two groups.Patients in treatment group（59 cases） were treated by entecavir combined with matrine while those in control group（50 cases） were treated by entecavir singly. The treatment lasted for 48 weeks in every group. Hepatitis B two pairs of semi，serum HBV DNA repli－cation level and alanine transaminase（ALT） were detected respectively before treatment and at the 24th，48th week after treatment. Quantitative data were analyzed by t-test and rank sum test while qualitative data by chi-square test. Results：HBeAg clearance rate，HBeAg/anti-HBe seroconversion，HBV DNA recovery rate were significantly higher in treatment group than in control group at the 24th week after treatment，with significant differences between two groups（P values were 0.021，0.044，0.042 respectively）. HBeAg clearance rate，HBeAg/anti-HBe seroconversion，HBV DNA recovery rate were significantly higher in treatment group than in control group at the 48th week after treatment，with significant differences between two groups（P values were 0.039，0.012，0.011 respective－ly）. There was no statistical difference in ALT normalization rate between two groups at the 24th，48th week treatment（P >0.05）. Conclusions：Entecavir combined with matrine is effective in the treatment of chronic hepatitis B and can significantly improve the biochemical indicators of patients.